{"title": "Dynamical System Modeling to Simulate Donor T Cell Response to Whole  Exome Sequencing-Derived Recipient Peptides: Understanding Randomness in  Clinical Outcomes Following Stem Cell Transplantation", "tag": "q-bio", "abstract": " Alloreactivity following stem cell transplantation (SCT) is difficult to predict in patients undergoing transplantation from HLA matched donors. In this study we performed whole exome sequencing of SCT donor-recipient pairs (DRP). This allowed determination of entire library of alloreactive peptide sequences which would bind HLA class I molecules in each DRP. Utilizing the HLA binding affinity (IC50) and tissue expression levels of the parent proteins, an aggregate donor T cell response to the recipient alloreactive peptides was calculated using a vector-operator dynamical system model. Marked variability in the simulated CD8+ T cell responses was observed in all the donor recipient pairs. ", "text": "center biological complexity bone marrow transplant program department internal medicine department biostatistics department psychiatry statistical genomics virginia reached several iterations represents maximum cell count system would support growth rate population; number iterations population gone cell population time following function cell population earlier time point turn depend cell population outset transplant intrinsic cell proliferative capacity normal donor presumably made mostly self-tolerant pathogen specific cells without auto-reactive cells. computations reported here cell clone value termed alloreactivity potential operator operator consist binding affinity modifying original donor cell vector system goes successive iterations recipient cell vector according following relationship central assumption model steady state clonal frequency specific bearing clones growth rates proportional binding affinity target mhahla complexes. approximately represented reciprocal modify vector simplified model mhax-hla effects matrix represents single iteration impact population growth multiple coexisting populations accomplished modifying expression equation clone taking competing cell populations calculating clone. clone’s weighted correction factor interaction cell clone examined. given central role target mha-hla complex’s determining cell frequency clone clone calculated dividing competing cell clone test clone implies cell clones recognizing mha-hla complexes higher binding cell clone depends cell clonal frequencies previous iteration cell clone respect cell clone modifying effect frequency clone tcx. contrast parameter either positive negative values depending whether ambient cytokine milieu either stimulates suppresses cell clones. example tolerant non-autoreactive cell clones transformed predominantly alloreactive cell clones interacting mhahla complex alloreactivity operator encountered recipient figure individual cell clonal growth simulations accounting peptide-hla complex binding affinity protein origin rpkm. increased cell frequency seen protein expressed higher level. ic/rpkm given cell clone. figure tissue specific simulated alloreactive cell counts recipients unrelated donors values represent entire cell vector responding alloreactivity operator matrix mha-hla complexes specific organ including negative values figure alloreactivity model. product cell vectors recapitulates familiar antigenchallenge driven cell proliferation response curve. single cell clone entire repertoire. model illustrating interaction cells. figure modeling effect treg effector cell growth curve reduced iteration cell population drops recovers slowly. blue curve reduced iteration direction reversal signifying anti-inflammatory effect supersedes pro-inflammatory effect. exome sequencing differences synonymous nonsynonymous conservative non-conservative hla-presented peptides peptides strong binders presented peptides percent strong binders percent presented peptides strong binders/presented peptides aexcludes haploidentical patient bmean values compared using t-test equality means mmrd mmud bone marrow peripheral blood acute lymphoid leukemia acute myeloid leukemia chronic lymphocytic leukemia lymphomas multiple myeloma myelodysplastic syndromes anti-thymocyte globulin reduced intensity atg/tbi busulfan/fludarabine fludarabine/melphalan myeloablative busulfan/cyclophosphamide cyclophosphamide/tbi etoposide/tbi cyclosporin a/methotrexate cyclosporin a/mmf tacrolimus/methotrexate tacrolimus/mmf acute grades i-ii acute grades iii-iv chronic both acute chronic table salivary glands colon esophagus small intestines* stomach liver lung skin total* *indicates sample sizes overall gvhd group missing value table salivary glands colon esophagus small intestines stomach liver lung skin total variance measures standard deviation minimum maximum range salivary glands colon esophagus small intestines stomach liver lung skin total standard deviation minimum maximum range *hazard ratio based t-cell counts expressed salivary glands colon esophagus small intestines stomach liver lung skin total standard deviation minimum maximum range *hazard ratio based t-cell counts expressed acknowledgements. work supported massey pilot project grant award virginia’s commonwealth health research board performed bioinformatic analysis sequencing data identify unique peptides binding affinity well tissue expression. wrote program performing calculations matlab performed vector-operator calculations presented paper. collected verified clinical outcome data. performed statistical analysis. performed sequencing samples identified procured mj-l created data files unique peptides values. authors contributed writing manuscript. kröger solano wolschke bandini patriarca pini nagler selleri risitano messina bethge pérez oteiza duarte carella cimminiello guidi finke mordini ferra sierra russo petrini milone benedetti heinzelmann pastore jurado terruzzi narni völp ayuk ruutu bonifazi antilymphocyte globulin prevention chronic graft-versus-host disease. engl med. ringdén labopin ciceri velardi bacigalupo arcese ghavamzadeh hamladji schmid nagler mohty stronger graft-versus-leukemia effect using hla-haploidentical donors compared hla-identical siblings? leukemia. feb;-. ciurea zhang bacigalupo bashey appelbaum aljitawi armand antin chen devine fowler luznik nakamura o'donnell perales pingali porter riches ringdén rocha weisdorf champlin horowitz fuchs eapen haploidentical transplant posttransplant cyclophosphamide matched unrelated donor transplant acute myeloid leukemia. blood. holtick albrecht chemnitz theurich shimabukuro-vornhagen skoetz scheid bergweltbaildon comparison bone marrow versus peripheral blood allogeneic hematopoietic stem cell transplantation hematological malignancies adults systematic review meta-analysis. crit oncol hematol. may;-. eapen logan horowitz zhong perales rocha soiffer champlin bone marrow peripheral blood reduced-intensity conditioning unrelated donor transplantation. clin oncol. inamoto flowers appelbaum carpenter deeg furlong kiem mielcarek nash storb witherspoon storer martin retrospective comparison tacrolimus versus cyclosporine methotrexate immunosuppression allogeneic hematopoietic cell transplantation mobilized blood cells. biol blood marrow transplant. jul;-. kanda kobayashi mori tanaka nakaseko yokota watanabe kako kakihana kato tanihara doki ashizawa kimura kikuchi kanamori okamoto kanto study group cell therapy.. randomized controlled trial cyclosporine tacrolimus strict control blood concentrations unrelated bone marrow transplantation. bone marrow transplant. jan;-. brunstein fuchs carter karanes costa devine wingard aljitawi cutler jagasia ballen eapen o'donnell blood marrow transplant clinical trials network.. alternative donor transplantation reduced intensity conditioning results parallel phase trials using partially hlamismatched related bone marrow unrelated double umbilical cord blood grafts. blood. el-cheikh crocchiolo furst bramanti sarina granata lemarie faucher mohty harbi bouabdallah santoro chabannon castagna blaise unrelated cord blood compared haploidentical grafts patients hematological malignancies. cancer. petersen alloreactivity therapeutic principle treatment hematologic malignancies. studies clinical immunologic aspects allogeneic hematopoietic cell transplantation nonmyeloablative conditioning. bull. may;-. toor sabo roberts moore salman scalora aziz shubar hall meier thorn wang song miller rizzo clark mccarty chung manjili neale dynamical system modeling immune reconstitution allogeneic stem cell transplantation identifies patients risk adverse outcomes. biol blood marrow transplant. jul;-. bayraktar milton guindani rondon chen al-atrash rezvani champlin ciurea optimal threshold time absolute lymphocyte count assessment outcome prediction bone marrow transplantation. biol blood marrow transplant. mar;-. storb gyurkocza storer maloney sorror mielcarek martin sandmaier allogeneic hematopoietic cell transplantation following minimal intensity conditioning predicting acute graft-versus-host disease graft-versus-tumor effects. biol blood marrow transplant. may;-. meier roberts avent hazlett berrie payne hamm desmarais sanders hogan archer manjili toor fractal organization human cell repertoire health stem cell transplantation. biol blood marrow transplant. mar;-. sampson sheth koparde scalora serrano roberts jameson-lee ferreiragonzalez manjili buck neale toor whole exome sequencing estimate alloreactivity potential donors recipients stem cell transplantation. haematol. aug;-. jameson-lee koparde griffith scalora sampson khalid sheth batalo serrano roberts hess buck neale manjili toor silico derivation hla-specific alloreactivity potential whole exome sequencing stem-cell transplant donors recipients understanding quantitative immunobiology allogeneic transplantation. front immunol. abdul razzaq scalora koparde meier mahmood salman jameson-lee serrano sheth voelkner kobulnicky roberts ferreira-gonzalez manjili buck neale toor dynamical system modeling simulate donor cell response whole exome sequencing-derived recipient peptides demonstrates different alloreactivity potential hla-matched -mismatched donor-recipient pairs. biol blood marrow transplant. may;-. pidala wang haagenson spellman askar battiwalla baxter-lowe bitan fernandez-viña gandhi jakubowski maiers marino marsh oudshoorn palmer prasad reddy ringden saber santarone schultz setterholm trachtenberg turner woolfrey anasetti amino acid substitution peptide-binding pockets class molecules increases risk severe acute gvhd mortality. blood. morrrison classification scheme dynamic systems modeling dynamic systems forecasting chaos randomness determinism. dover publications mineola ringdén labopin solders beelen arnold ehninger milpied niederwieser hamladji kyrcz-krzemien ganser socié stelljes volin craddock mohty acute leukaemia working party european group blood marrow transplantation.. best hematopoietic stem-cell donor male patient acute leukemia? transplantation. morishima kashiwase matsuo azuma morishima onizuka yabe murata doki mori miyamura ichinohe saji kato atsuta kawa kodera sasazuki japan marrow donor program.. biological significance locus matching unrelated donor bone marrow transplantation. blood. valcárcel sierra wang gupta hale marks mccarthy oudshoorn petersdorf ringdén setterholm spellman waller gajewski marino senitzer one-antigen mismatched related versus hla-matched unrelated donor hematopoietic stem cell transplantation adults acute leukemia center international blood marrow transplant research results molecular typing. biol blood marrow transplant. may;-. battiwalla marino setterholm ringden hurley flomenberg anasetti fernandez-vina hla-c antigen mismatch associated worse outcome unrelated donor peripheral blood stem cell transplantation. biol blood marrow transplant. jun;-. pérez oteiza duarte carella cimminiello guidi finke mordini ferra sierra russo petrini milone benedetti heinzelmann pastore jurado terruzzi narni völp ayuk ruutu cutler koreth alyea mcafee soiffer chen antin addition sirolimus graft-versus-host disease prophylaxis regimen reduced intensity allogeneic stem cell transplantation lymphoma multicentre randomized trial. haematol. apr;-. nikiforow ritz blazar soiffer antin alyea bortezomib-based regimen offers promising survival graft-versus-host disease prophylaxis myeloablative hla-mismatched unrelated donor transplantation phase trial. biol blood marrow transplant. nov;-. ehninger johnston maziarz pulsipher porter mineishi mccarty khan anderlini bensinger leitman rowley bredeson carter horowitz confer blood marrow transplant clinical trials network.. peripheral-blood stem cells versus bone marrow unrelated donors. engl med. fegueux clement sandstedt maertens guillerm bordessoule mohty nagler high peripheral blood stem cell grafts content associated increased risk graft-versus-host disease without beneficial effect disease control reduced-intensity conditioning allogeneic transplantation matched unrelated donors acute myeloid leukemia analysis acute leukemia working party european society blood marrow transplantation. oncotarget. gervais haagenson horowitz jindra madrigal oudshoorn ringdén schroeder spellman tiercy velardi witt o'huigin apps carrington international histocompatibility working group hematopoietic cell transplantation.. hla-c expression levels define permissible mismatches hematopoietic cell transplantation. blood. wang stevenson high hla-dp expression graft-versus-host disease. engl med. kaech transcriptional control effector memory cell differentiation. immunol. nov;-. differentiation. front genet. bevan helping t-cell response. immunol. aug;-. pandiyan zheng lenardo molecular mechanisms regulatory cell immunosuppression. frontiers immunology. doi./fimmu...", "year": "2016"}